U.S. Food and Drug Administration (FDA) Denies Abbott's Attempt to Block Generics

Abbott Laboratories was informed today by the U.S. Food and Drug Administration (FDA) that the company's Citizen Petition filed in August 2003 regarding bioequivalence of levothyroxine sodium products has been denied. This means that Synthroid brand levothyroxine, the second most prescribed drug in the U.S., is now subject to generic competition. SYNTHROID is the second-most-prescribed drug in the United States.